PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Banner Health
Study ID
NCT07178808
Phase
PHASE2
Status
Recruiting

Conditions

  • Gastric Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy — PROCEDURE
    CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use of heated and high dose chemotherapy to address microscopic residual disease.

Study Details

This is a Phase II treatment study analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC in gastric adenocarcinoma patients with cytology-positive only carcinomatosis, radiologically-occult carcinomatosis, or radiology apparent peritoneal-surface only metastatic disease.

Key Dates

Start date
Apr 16, 2021
Status verified
Sep 2025
Primary completion
Feb 22, 2031
Completion
Feb 22, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Patients will undergo cytoreduction \& hyperthermic intraperitoneal chemotherapy

Primary Outcome Measure

To assess improvements in survival in gastric adenocarcinoma patients with occult or apparent carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [ Time Frame: From enrollment up to 60 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234
James Schohn
480-256-3310
Klarissa Jones
602-747-3647
Rajesh Ramanathan (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gilbert, AZ

Related Studies